{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:06:12Z","timestamp":1789607172635,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100021535","name":"Albert Schweitzer Fellowship","doi-asserted-by":"publisher","award":["2024_02"],"award-info":[{"award-number":["2024_02"]}],"id":[{"id":"10.13039\/100021535","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vincristine dose reduction during R\u2010CHOP treatment of diffuse large B\u2010cell lymphoma (DLBCL) is frequently required due to vincristine\u2010induced polyneuropathy (VIPN). Previous studies suggested an association between vincristine relative dose intensity and inferior outcomes. However, it remains unclear whether this applies to selective vincristine dose reduction or is mainly related to combined reductions of other chemotherapeutic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated treatment outcomes of patients newly diagnosed with advanced\u2010stage DLBCL treated with R\u2010CHOP between 2015 and 2021. Patients were categorized as receiving full\u2010dose R\u2010CHOP, selective vincristine dose reduction, or combined reductions of R\u2010CHOP components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 196 included patients, the 5\u2010year overall survival (OS) was 84% in patients with a selective vincristine dose reduction and 79% in patients receiving full\u2010dose. In multivariable analyses, selective vincristine dose reduction was not associated with inferior progression\u2010free survival or OS. In contrast, lower cumulative doxorubicin dose was associated with inferior treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Selective vincristine dose reduction due to VIPN was not associated with inferior progression\u2010free or OS in patients with DLBCL treated with R\u2010CHOP. These findings support vincristine dose reduction for management of VIPN while maintaining adequate doxorubicin dose intensity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70321","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:01:22Z","timestamp":1789606882000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Vincristine Dose Reduction on Outcomes of Patients With Advanced\u2010Stage Diffuse Large B\u2010Cell Lymphoma Treated With R\u2010\n                    <scp>CHOP<\/scp>"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9512-1379","authenticated-orcid":false,"given":"Jantina P.","family":"Kortleve","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Albert Schweitzer Hospital  Dordrecht the Netherlands"},{"name":"Department of Hematology St. Antonius Hospital  Nieuwegein the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2873-0834","authenticated-orcid":false,"given":"Sofie","family":"Engels","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Albert Schweitzer Hospital  Dordrecht the Netherlands"},{"name":"Faculty of Medicine Erasmus University\/Erasmus Medical Center  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber A.","family":"Zweers","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-5725","authenticated-orcid":false,"given":"Yasmina","family":"Serroukh","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark\u2010David","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Albert Schweitzer Hospital  Dordrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-5794","authenticated-orcid":false,"given":"Eva","family":"de Jongh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Albert Schweitzer Hospital  Dordrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Sikorska","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute  Rotterdam the Netherlands"},{"name":"HOVON Foundation  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0960-062X","authenticated-orcid":false,"given":"Aurelia H.","family":"de Vries Schultink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Utrecht University Medical Centre  Utrecht the Netherlands"},{"name":"Department of Clinical Pharmacy St. Antonius Hospital  Nieuwegein the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel P. H.","family":"van den Broek","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy St. Antonius Hospital  Nieuwegein the Netherlands"},{"name":"Department of Pharmaceutical Sciences Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-7039","authenticated-orcid":false,"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Albert Schweitzer Hospital  Dordrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"S\u00f6hne","sequence":"additional","affiliation":[{"name":"Department of Hematology St. Antonius Hospital  Nieuwegein the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"20","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow S. H.","year":"2016","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma Incidence Patterns by WHO Subtype in the United States. 1992\u20102001","volume":"107","author":"Morton L. M.","year":"2006","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse Large B\u2010Cell Lymphoma: Optimizing Outcome in the Context of Clinical and Biologic Heterogeneity","volume":"125","author":"Sehn L. H.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_12_5_1","unstructured":"HOVON \u201cRichtlijn Diffuus Grootcellig B\u2010cel Non\u2010Hodgkin LymFoom \u201d 2021 https:\/\/hovon.nl\/_asset\/_public\/TreatmentGuidelines\/TreatmentGuidelines_Lymphoma\/Richtlijn\u2010DLBCL\u2010_NVvH_2021.pdf."},{"issue":"2","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ajh.27151","article-title":"R\u2010miniCHOP Versus R\u2010CHOP in Elderly Patients With Diffuse Large B\u2010Cell Lymphoma: A Propensity Matched Population\u2010Based Study","volume":"99","author":"Al\u2010Sarayfi D.","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"1","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1756-9966-28-116","article-title":"Impact of Relative Dose Intensity (RDI) in CHOP Combined With Rituximab (R\u2010CHOP) on Survival in Diffuse Large B\u2010Cell Lymphoma","volume":"28","author":"Terada Y.","year":"2009","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"9","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of Maintaining the Relative Dose Intensity of CHOP\u2010Like Regimens Combined With Rituximab in Patients With Diffuse Large B\u2010Cell Lymphoma","volume":"89","author":"Hirakawa T.","year":"2010","journal-title":"Annals of Hematology"},{"issue":"3","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2020.12.017","article-title":"Impact of Omission\/Reduction of Vincristine From R\u2010CHOP in Treatment of DLBCL","volume":"21","author":"Marshall S.","year":"2021","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"12","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long\u2010Term Outcome of Patients in the LNH\u201098.5 Trial. The First Randomized Study Comparing Rituximab\u2010CHOP to Standard CHOP Chemotherapy in DLBCL Patients: A Study by the Groupe D'etudes Des Lymphomes de L'adulte","volume":"116","author":"Coiffier B.","year":"2010","journal-title":"Blood"},{"issue":"9873","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine Plus Rituximab Versus CHOP Plus Rituximab as First\u2010Line Treatment for Patients With Indolent and Mantle\u2010Cell Lymphomas: An Open\u2010Label. Multicentre Randomised. Phase 3 Non\u2010Inferiority Trial","volume":"381","author":"Rummel M. J.","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.WNL.0000154642.45474.28","article-title":"Dose\u2010Related Vincristine\u2010Induced Peripheral Neuropathy With Unexpected Off\u2010Therapy Worsening","volume":"64","author":"Verstappen C. C.","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jns.12114","article-title":"Patterns and Severity of Vincristine\u2010Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia","volume":"20","author":"Lavoie Smith E. M.","year":"2015","journal-title":"Journal of the Peripheral Nervous System: JPNS"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine\u2010Induced Peripheral Neuropathy: A Mini\u2010Review","volume":"81","author":"Li G. Z.","year":"2020","journal-title":"Neurotoxicology"},{"issue":"2","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy\u2010Induced Peripheral Neuropathy: Epidemiology. Pathomechanisms and Treatment","volume":"9","author":"Burgess J.","year":"2021","journal-title":"Oncology and Therapy"},{"issue":"1","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01050259","article-title":"Long\u2010Term Effects of Vincristine on the Peripheral Nervous System","volume":"15","author":"Postma T. J.","year":"1993","journal-title":"Journal of Neuro\u2010Oncology"},{"issue":"1","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00277-015-2514-9","article-title":"Influence of Dose Reduction of Vincristine in R\u2010CHOP on Outcomes of Diffuse Large B Cell Lymphoma","volume":"95","author":"Utsu Y.","year":"2016","journal-title":"Annals of Hematology"},{"issue":"9","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1007\/s00520-021-06059-2","article-title":"Vinorelbine as Substitute for Vincristine in Patients With Diffuse Large B Cell Lymphoma and Vincristine\u2010Induced Neuropathy","volume":"29","author":"Hatzl S.","year":"2021","journal-title":"Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"11","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00277-018-3437-z","article-title":"Does the Omission of Vincristine in Patients With Diffuse Large B Cell Lymphoma Affect Treatment Outcome?","volume":"97","author":"M\u00f6rth C.","year":"2018","journal-title":"Annals of Hematology"},{"issue":"1","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the Molecular Classification of Diffuse Large B\u2010Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray","volume":"103","author":"Hans C. P.","year":"2004","journal-title":"Blood"},{"issue":"3","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an Assessment Tool for Grading the Course of Chemotherapy\u2010Induced Peripheral Neurotoxicity: Comparison With the National Cancer Institute\u2010Common Toxicity Scale","volume":"12","author":"Cavaletti G.","year":"2007","journal-title":"Journal of the Peripheral Nervous System: JPNS"},{"issue":"2","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The Chemotherapy\u2010Induced Peripheral Neuropathy Outcome Measures Standardization Study: From Consensus to the First Validity and Reliability Findings","volume":"24","author":"Cavaletti G.","year":"2013","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"1","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.51.1","article-title":"Importance of Relative Dose Intensity in Chemotherapy for Diffuse Large B\u2010Cell Lymphoma","volume":"51","author":"Yamaguchi H.","year":"2011","journal-title":"Journal of Clinical and Experimental Hematopathology"},{"issue":"6","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/joim.12889","article-title":"Impact of Intended and Relative Dose Intensity of R\u2010CHOP in a Large. Consecutive Cohort of Elderly Diffuse Large B\u2010Cell Lymphoma Patients Treated With Curative Intent: No Difference in Cumulative Incidence of Relapse Comparing Patients by Age","volume":"285","author":"Eyre T. A.","year":"2019","journal-title":"Journal of Internal Medicine"},{"issue":"9","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R\u2010CHOP Dose Intensity on Survival Outcomes in Diffuse Large B\u2010Cell Lymphoma: A Systematic Review","volume":"5","author":"Bataillard E. J.","year":"2021","journal-title":"Blood Advances"},{"issue":"5","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14740\/jh1054","article-title":"Oral Chemotherapy Application in Elderly Patients With Diffuse Large B\u2010Cell Lymphoma: An Alternative Regimen in Retrospective Analysis","volume":"11","author":"Liao P. H.","year":"2022","journal-title":"Journal of Hematology"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70321","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:01:32Z","timestamp":1789606892000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":25,"alternative-id":["10.1111\/ejh.70321"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70321","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"2025-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70321"}}